Still’s disease is a form of arthritis. Stills disease is characterized by high spiking fevers and evanescent (transient) salmon-colored rash (view pictures of the Still’s rash). Still’s disease was first described in children, but it is now known to occur, much less commonly, in adults (it is referred to as Adult-onset Still’s disease, AOSD). There are 2 concepts for the cause: 1st is assumed to be that Still’s disease is due to infection with a microbe. Another concept is that Still’s disease is a hypersensitive or autoimmune disorder. Yet the cause of Still’s disease is still not known. Interleukin
Diagnosis for Still’s disease develops markedly elevated white blood cell counts, as if they have a serious infection but none is found. Low red blood counts (anemia) and elevated blood tests for inflammation (such as sedimentation rates) are common. However, the classic blood tests for Rheumatoid Arthritis (rheumatoid factor) and systemic Lupus erythematosus (antinuclear antibodies, ANA) are usually negative. Still’s disease usually present with systemic (body wide) symptoms. Extreme fatigue can have high fevers that rise to 104 degrees F (41 degrees C) or even higher and rapidly return to normal levels or below. A faint salmon-colored skin rash. There is commonly swelling of the lymph glands, enlargement of the spleen and liver, and sore throat. This usually involves many joints (polyarticular arthritis). Any joint can be affected, although there are preferential patterns of joint involvement in Still’s disease.
Cyclophosphamide. There is a new class of drugs called biologics that are very promising in treating Still’s. Enbrel, Remicade, Kineret and several others are available and are being used as a first line therapy in treating still’s meaning you don’t have to take Methotrexate
The approximate Adult Stills Disease Incidence in North America, USA was found to be 39,945,772. Adult-onset Still's Disease is rare and has been described all over the world. The number of new cases of AOSD per year is estimated to be 0.16 new cases per 100,000 populations. Prevalence is estimated at 1.5 cases per 100,000-1,000,000 population